Brainstorm Cell Therapeutics Inc. (BCLI)
| Market Cap | 112.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.08M |
| Shares Out | 36.28M |
| EPS (ttm) | -0.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,034 |
| Open | 3.24 |
| Previous Close | 3.24 |
| Day's Range | 3.05 - 3.31 |
| 52-Week Range | 2.75 - 8.14 |
| Beta | -0.10 |
| Analysts | Buy |
| Price Target | 11.00 (+254.8%) |
| Earnings Date | Feb 2, 2022 |
About BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is ...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BCLI stock is "Buy" and the 12-month stock price forecast is 11.00.
News
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Ke...
FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program
NEW YORK, Dec. 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing ext...
BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publ...
BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing
NEW YORK and SOMERSET, N.J., Dec. 7, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: ...
BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on ...
BrainStorm Cell ALS Candidate Shows Benefit In Patients With Less Severe Disease
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) has announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium. The NurOwn technology platf...
BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at t...
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ne...
BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for ...
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments ...
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors
NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Men...
BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will ...
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a ...
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Commi...
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicent...
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstr...
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph...
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
NEW YORK, Oct. 1, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstr...
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
NEW YORK, Aug. 5, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for t...
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
NEW YORK, July 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received G...
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
NEW YORK, July 26, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will h...
Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications ...
NEW YORK, June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant an...
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUA...
NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a p...
BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update
NEW YORK, April 26, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for...
BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update
NEW YORK, April 19, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will...
BrainStorm Cell Stock Surges As NurOwn Aces Mid-Stage Multiple Sclerosis Study
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) has reported topline Phase 2 data evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given two months apart, as a treatment for pro...
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS
NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data f...